Basic Information
Jaypirca
Regulatory Information
EMEA/H/C/005863
October 30, 2023
April 26, 2023
2
November 20, 2023
Company Information
Netherlands
Papendorpseweg 83 3528 BJ Utrecht
Eli Lilly Nederland BV
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of mantle cell lymphoma (MCL)
Overview Summary
Jaypirca is a cancer medicine used to treat adults with mantle cell lymphoma (a cancer of B cells, a type of white blood cell) whose cancer has come back (relapsed) or no longer responds to treatment (refractory), and who had previously received a type of cancer medicine called a Bruton’s tyrosine kinase (BTK) inhibitor. Mantle cell lymphoma is rare, and Jaypirca was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2021. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2450). Jaypirca contains the active substance pirtobrutinib.